Company Monitoring Page for Exelixis

latest headlines for company on cafepharma

Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis
Motley Fool
Sat, 05/24/14 - 09:50 am
Tags:
Ariad Pharmaceuticals, Exelixis
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Motley Fool
Fri, 05/2/14 - 08:37 am
Tags:
earnings, Exelixis
1 of These 3 Cratering Biotechs is a Buy
Motley Fool
Sun, 04/20/14 - 09:27 am
Tags:
Halozyme, Exelixis, Vivus
Is This the Year Exelixis Excels?
Morningstar
Fri, 03/28/14 - 10:06 am
Tags:
Exelixis, Cometriq, prostate cancer
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis
TheStreet.com
Wed, 03/26/14 - 12:38 pm
Tags:
prostate cancer, Exelixis, cabozantinib
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data
Motley Fool
Thu, 02/20/14 - 05:31 pm
Tags:
Exelixis, earnings
What's Next for This Biotech?
Motley Fool
Wed, 11/6/13 - 03:32 pm
Tags:
Exelixis
Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013
Yahoo/BusinessWire
Sat, 09/28/13 - 10:44 am
Tags:
metastatic melanoma, melanoma, Exelixis, Cobimetinib
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Yahoo/Fly on the Wall
Thu, 09/26/13 - 08:19 am
Tags:
Exelixis, cabozantinib, metastatic castration-resistant prostate cancer
An Excellent Investment in the Biotech Space?
Motley Fool
Sat, 09/21/13 - 10:08 am
Tags:
Cometriq, medullary thyroid cancer, Exelixis
Will the Exelixis Hype Catch Up to Its Valuation?
Motley Fool
Tue, 09/17/13 - 11:04 am
Tags:
Exelixis, Cometriq, medullary thyroid cancer
The Best- And Worst-Performing Biotech Stocks July 19 To July 26
Forbes
Mon, 07/29/13 - 12:27 pm
Tags:
TearLab, Array Biopharma, Furiex Pharmaceuticals, InterMune, Prosensa, Boston Scientific, Orexigen, Momenta, Ironwood, INSYS Therapeutics, Sequenom, OncoMed, Abraxis, Sarepta, Epizyme, Tesaro, Synta Pharmaceuticals, Bluebird Bio, Exelixis, Lexicon Pharmaceuticals, Intercept Pharma, GTx
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Yahoo/BusinessWire
Sun, 06/2/13 - 11:41 am
Tags:
Exelixis, Cometriq, thyroid cancer, medullary thyroid cancer
Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Yahoo/BusinessWire
Sat, 06/1/13 - 12:17 pm
Tags:
Exelixis, cabozantinib, prostate cancer
Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players
Motley Fool
Mon, 04/29/13 - 05:24 pm
Tags:
thyroid cancer, Caprelsa, AstraZeneca, Cometriq, Exelixis, Nexavar, Bayer, ONYX Pharmaceuticals
Where Is Exelixis In The Cancer Therapeutics Market?
Seeking Alpha
Mon, 04/1/13 - 11:01 am
Tags:
Exelixis, cabozantinib, Cometriq, cancer
Why Exelixis Is Ready to Rebound
Motley Fool
Sun, 03/3/13 - 11:48 am
Tags:
Exelixis
Exelixis Earnings: Everything You Must Know Now
Wall St. Cheat Sheet
Fri, 02/22/13 - 11:09 am
Tags:
earnings, Exelixis
What's Ahead for Exelixis?
Motley Fool
Sun, 02/3/13 - 11:36 am
Tags:
Exelixis
Genentech takes Exelixis drug into Phase III melanoma trial
Bizjournals.com
Thu, 01/17/13 - 10:19 am
Tags:
Exelixis, Genentech, melanoma, Roche, Zelboraf, GDC-0973

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.